into the involvement of PKC in BD. In addition, the effect of PKC inhibitors, such as tamoxifen, in the resolution of manic symptoms in patients with BD further points in that direction. Furthermore, a wide variety of growth factors influence neurotransmission through several molecular pathways that involve downstream effects of PKC. Our current understanding identifies the PKC pathway as a potential therapeutic avenue for BD.
Introduction
Bipolar disorder (BD) is a chronic and life-threatening disorder, and has been identified as one of the leading causes of disability worldwide [1] . BD is classically characterized by recurrent fluctuation between distinct periods of both positive (mania) and negative (depression) extremes of mood state. Additional features frequently associated with BD are impairment in emotion perception, affect regulation, attention, and executive function-ing [2] . These impairments also correlate with structural and functional abnormalities in frontolimbic brain regions, such as prefrontal cortex (PFC), hippocampus, and amygdala, that regulate emotion, memory, and motivated behavior [3] . Despite its heavy toll on human lives, the molecular mechanisms underlying the pathogenesis of BD remain elusive.
Initial insights into the pathophysiology BD were gained in 1980s after the serendipitous discovery of lithium [4] and valproic acid [5] as effective mood stabilizers. In the past 10 years, several animal models of mania have been developed to mimic human BD [6] . The manic phenotype is usually induced in animal models by pharmacological (amphetamine [AMPH] and ouabain), environmental (paradoxical sleep deprivation [PSD] ), and genetic (black Swiss mice) interventions [6] . These interventions induce behavioral changes that are analogous to manic symptoms, such as hyperlocomotion [7] , insomnia, risktaking behavior [8] , and increased appetitive 50-kHz ultrasonic vocalizations (USV; a marker for euphoric mood and pressured speech) [9] . These models are tested for their face (animals mimicking manic symptoms), construct (correlation of similar pathophysiological alteration at molecular level), and predictive (amelioration of symptoms by currently accepted treatments of mania) validity to enhance our understanding of BD [10] . Our advances in neuroimaging techniques, such as in vivo magnetic resonance imaging, and novel genetic approach, such as convergent functional genomics, are providing us endophenotypic characteristics of BD [11] . After 3 decades of intensive preclinical and translational research, protein kinase C (PKC) has come to be recognized to play a central role in the pathophysiology of BD [12] [13] [14] .
The protein kinase family of proteins is one of the largest superfamily of nearly 500 proteins that are evolutionarily conserved across 11 eukaryotic species and regulate various cellular events [15, 16] . The PKC family includes 10 serine/threonine protein kinases that are encoded by 9 mammalian genes and reversibly phosphorylate serine, threonine, and tyrosine residues in their target proteins [15] . These 10 kinases are subdivided into 3 subfamilies based on their structure and their regulatory cofactors, namely classical or conventional PKC [cPKC: α, β I , β II , and γ; regulated by phospholipids, Ca 2+ ions, and diacylglycerol (DAG)], novel PKC (nPKC: ε, δ, η, θ, and μ; regulated by phospholipid and DAG), and atypical PKC (aPKC: ξ, Mξ, ι, and λ; regulated by phospholipids but are independent of DAG and Ca 2+ ions) [17] . All PKCs consist of a highly conserved C-terminal catalytic domain and a nonconserved N-terminal regulatory domain [18] .
In the CNS, cPKC subfamily enzymes, PKCα, -β, and -γ, are most abundantly expressed [19] and influence neuronal signaling by short-term (neurotransmitter release and ion fluxes), medium-term (receptor regulation), and long-term (cell proliferation, synaptic remodeling, and gene expression) mechanisms [20] . PKC isozymes are highly expressed in the frontolimbic structures, such as PFC, hippocampus, and amygdala, which are involved in mood regulation [21, 22] . PKC is inhibited by mood stabilizers such as lithium and valproic acid [14] . Additionally, PKC signaling is involved in the regulation of processes that are affected in BD, such as neuronal excitability [23] , neurotransmitter release [24, 25] , glutamatergic neurotransmission [26] , neuroplasticity [27] , apoptotic pathway activation [28] , mitochondrial dysfunction, and oxidative stress [29] , and neuroinflammation [30] [31] [32] .
We searched PubMed database with key words "protein kinase C bipolar disorder" and "PKC bipolar disorder" and selected articles since 2008. Few earlier manuscripts are tabulated in the article to provide a historical context of recent observations. We reviewed a total of 26 studies (9 in vitro, 11 in vivo, and 6 clinical studies). We organized our narrative to address proposed pathophysiological mechanisms underlying BD, including: (1) PKC translocation and activity; (2) putative downstream molecular effects, and (3) gene candidates. The studies are indexed in Tables 1-4 .
PKC Translocation and Activity

Preclinical Studies
The importance of hyperactive PKC signaling in BD was first appreciated when commonly used mood stabilizers, both lithium and valproic acid, were observed to inhibit PKC activity in vitro [33, 34] and in vivo [35] [36] [37] . Later, the levels of membrane-associated PKC were shown to decrease after exposure to lithium and valproic acid, in vitro [38] and in vivo [39, 40] . These observations were corroborated in humans when chronic treatment with lithium decreased PKC signaling in euthymic patients with BD [41] . One of the mechanisms underlying this mitigation of PKC hyperactivity by lithium and valproic acid is the inhibition of its translocation from cytosol to cell membrane. PKC is known to translocate to cell membrane when stimulated by phorbol esters (phorbol 12-myristate 13-acetate [PMA]), serotonin (5HT), K + ions [42] , and DAG analogs in vitro [43] and ex vivo [34] . It has been shown that platelets from patients in acute mania show enhanced 5HT-induced PKC translocation and membrane-bound PKC activity than controls, which is reversed after lithium treatment [44] . Brain slices from lithium-fed rats displayed inhibited stimulus-induced membrane translocation of PKC without affecting its baseline activity [42] . Moreover, PKC is pharmacologically activated by PMA, which provides DAG substitute [45] . PKC activation by direct infusion of PMA in the PFC of rodents and monkeys was shown to induce distractibility, impaired judgment, impulsivity, and thought disorder, which are characteristic symptoms of BD [46] . Furthermore, in rodents, infusion of PMA in the hippocampus, but not in lateral ventricle, was also found to have antidepressant-like effects, and induce enhanced risk-taking behavior [8] .
With the development of animal models of mania in the past 2 decades, the involvement of PKC in manic phenotype has become more apparent. Increased PKC activity is observed in the PFC of rats submitted to AMPH administration [47, 48] . AMPH-induced hyperlocomotion has been shown to be reversed [7] and prevented [49] by intraperitoneal administration of lithium or tamoxifen (TMX), a selective estrogen receptor modulator with PKC inhibitory activity [8, 50] . Similarly, intraperitoneal administration of quercetin, a nonspecific PKC inhibitor, also prevented methylphenidate-induced hyperlocomotion [51] . Not only in the presence of pharmacological intervention, daily intraperitoneal administration of lithium or TMX alone for 7 days significantly decreases phosphorylated PKC (pPKC) in the hippocampus, PFC, amygdala, and striatum [7] . Furthermore, chronic administration (14 days) of TMX caused depressive-like behavior in the forced swim test, and resulted in a reduction of cell proliferation in the dentate gyrus of the hippocampus [8] .
Sleep-deprived rats display paradoxical hyperlocomotion, increased penile erection, and insomnia [48] . Sleepdeprived animals did not display manic phenotype when they were pretreated with lithium or TMX or their combination [52] . Intraperitoneal administration of quercetin also prevented PSD-induced hyperlocomotion [53] . Interestingly, PSD-induced behavioral changes were reversed by a one-time administration of lithium about 1 h prior to behavioral testing without affecting baseline activity [48] . At cellular level, PSD decreased hippocampal cell proliferation as indicated by decreased bromodeoxyuridine labeling [48] . Again, single administration of lithium increased BrdU-labeled hippocampal neurons in sleep-deprived rats highlighting potent neuroprotective actions of lithium [48] . Pereira et al. [9] observed that AMPH increases appetitive 50-kHz USV. The USV are emitted by rodents in association with social communication and reward behavior such as mating [54] . The authors, hence, reasonably propose that AMPH-induced increase in USV simulates euphoric affect and pressured speech that is observed in patients with BD during acute mania [9] . In support of its predictive validity, pretreatment of rats with Li or TMX blocked the increase in USV calls induced by AMPH without affecting spontaneous call rates or locomotor activity [9] . Myricitrin, another PKC inhibitor, also prevented the increased USV induced by AMPH in a dose-dependent manner without affecting baseline call rate at any of the doses used [9] . PKC is also commonly inhibited by chelerythrine, a benzophenanthridine alkaloid that was identified as a selective PKC inhibitor in 1990 [55] . Since then, it is widely used to investigate the role of PKC in several biological systems such as neuro-and cancer biology [56] . After several years of controversy regarding its selectivity [57] [58] [59] , it has recently been shown that chelerythrine influences intracellular calcium homeostasis independent of PKC [60] . In animal models of mania, administration of chelerythrine prevented manic phenotype induced by AMPH [8] . While inhibition of PKC was concluded as the underlying mechanism by the authors, it is plausible that its effect on calcium homeostasis may have been involved in this observation [61] . In support of this alternative expla- DGKH1 expression was increased in peripheral blood of risk variant carriers; PKCD expression was significantly elevated in fibroblasts from DGKH risk variant carriers; current depressive episode had lower PKC delta levels, and lithium treatment was found to be associated with elevated PKC alpha levels BD, bipolar disorder; PIP2, phosphatidylinositol-4,5-bisphosphate; RACK-1, receptor for activated C kinase-1; PLC, phospholipase C; MARCKS, myristoylated alanine-rich C-kinase substrate; PMA, phorbol esters (phorbol 12-myristate 13-acetate); GWAS, genomewide association study; SNP, single nucleotide polymorphism; SI, suicidal ideations; SAT1, spermidine/spermine N1-acetyltransferase; PTEN, phosphatase and tensin homolog (PTEN); MAP3K3, mitogen-activated protein kinase kinase kinase 3; DGKH, gene coding for diacylglycerol kinase; PKCD, gene coding for PKC delta; CFG, convergent functional genomics; VPA, valproic acid. [40, 62, 63] . Verapamil, a calcium channel blocker with PKC inhibitory activity, is reported to significantly improve manic symptoms when combined with lithium [64] .
Clinical Studies
In patients with BD, PKC activity is studied mostly in the postmortem brain sample and platelets (usually during acute manic episode). A study in cortical homogenates of patients with BD showed that PKC levels and membrane-bound PKC activity were found to be increased in comparison with healthy controls [65] . PKC is anchored in the membrane by receptor for activated C kinase-1 (RACK-1) [66] . In frontal cortical homogenate, membrane PKC was found to be associated more with RACK-1 in BD samples [67] . Furthermore, in vitro stimulation of PKC by PMA produced enhanced stimulusinduced association between PKC and RACK-1 in samples from BD subjects in comparison to matched controls [67] . Platelets from manic patients also show higher membrane-bound PKC activity in comparison with healthy controls and patients with depression and schizophrenia [40, 68] . Moreover, chronic treatment with lithium has been observed to decrease both cytosolic and membrane-bound PKC levels in platelets from patients with BD [69] .
Further support to PKC hyperactivity in BD is drawn from the use of TMX in human BD patients. TMX is a prodrug with little affinity towards estrogen receptor, but its metabolites have high affinity and compete with estrogen for binding [70] . TMX also displays PKC inhibitory activity [71] and is the only PKC inhibitor that crosses the blood brain barrier [72] . In 2000, Bebchuk et al. [73] reported a proof-of-concept study in which TMX resolved acute manic symptoms in humans for the first time. Since then, several small-scale clinical trials have been conducted to test the utility of TMX in BD management [74] [75] [76] [77] . Patients with BD managed with TMX for 3 weeks showed a marked improvement in their manic presentation in as early as 5 days, an effect that remained significantly different throughout the 3-week trial [76] . TMX is also effective as an adjunct to lithium or valproic acid [78] . In a longer double-blind, randomized, placebo-controlled 6-week study, it was demonstrated that the combination of TMX with Li was superior to Li alone for the rapid reduction of manic symptoms [79] . Furthermore, TMX has also been reported to be an effective antimanic treatment in pediatric population [80] . In a recent meta-analysis, TMX was found to be effective as monotherapy and as an adjunctive treatment for manic symptoms [13] . Recently, monotherapy with endoxifen, a metabolite of TMX and a potent PKC inhibitor [81] , was found to be as effective as with valproic acid (extended release 1,000 mg/day) in mitigation of manic symptoms [82] . Interestingly, medroxyprogesterone acetate, a progestin, also shows significant improvement in mania symptoms and may have a therapeutic utility in the future [77, 78] .
BD is also associated with inefficient energy homeostasis in the brain, including decreases in mitochondrial respiration, high-energy phosphates, pH, along with changes in mitochondrial morphology, increases in mitochondrial DNA polymorphisms, downregulation of nuclear mRNA molecules and proteins involved in mitochondrial respiration [83] [84] [85] , and decreased neuronal viability marker, N-acetylaspartate (NAA) [86] . Recently, in a double-blind placebo-controlled magnetic resonance spectroscopy study, TMX was shown to increase total creatinine and NAA in dorsomedial PFC in patients with BD, suggesting enhanced neuronal viability [87] .
In contrast to putative hyperactive PKC signaling in BD, Young et al. [88] did not observe any significant difference in PKCα levels and activity between platelets from control, drug-free BD patients, and lithium-treated BD patients. In another contradictory finding in a recent report, Hayashi et al. [61] reported increased PKC activity in response to lithium in cultured adipocytes from patients with BD. These conflicting observations could be due to differences in patient characteristics and differences in tissues studied, respectively. In addition, the latter observation also implies that lithium may have tissuespecific actions on PKC signaling.
Downstream Targets of PKC
In addition to corroborating hyperactive PKC signaling in BD, studying downstream targets of PKC in BD may yield additional therapeutic targets. We will discuss recent work that has identified key downstream substrates of PKC such as neurogranin, neurotrophic factors (NTFs), growth-associated protein 43 (GAP-43; and several aliases such as B-50, F1, and neuromodulin), myristoylated alanine-rich C-kinase substrate (MARCKS), synaptosomal-associated protein 25 (SNAP-25), along with effect of PKC on glutamatergic neurotransmission, oxidative stress, apoptotic, and cyclic AMP signaling ( Fig. 1 ) .
Neurogranin is a brain-specific calmodulin-binding protein that is expressed in the dendritic spines [47] . Neu-rogranin is also a postsynaptic PKC substrate [89] , regulates synaptic plasticity [90] , and is implicated in schizophrenia [91, 92] . In both AMPH and PSD models, along with imipramine treated rats, phosphorylation of neurogranin was increased [47] . Interestingly, neurogranin phosphorylation, which is associated with promanic interventions, was reversed by lithium [47] . Moreover, cultured hippocampal neurons have also been observed to lose their dendritic spines in response to sustained activation of PKC [93] .
NTFs, such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-3, are observed to regulate gene expression and regulate synaptic plasticity via PKC signaling [94, 95] . Furthermore, PKC not only acts as a second messenger but BDNF and NGF also modulate the activity of PKC [96, 97] . PKC, in turn, influence the expression of NTFs, such as NGF [98] , BDNF [99] , and glial cell line-derived neurotrophic factor [100] . These observations underscore the complexity and interdependence of these signaling cascades that fine-tune the synaptic strength. In vivo, AMPH-treated rats show increased PKC but decreased BDNF and NGF expression [7] . This reduction in NTFs was reversed by lithium and TMX [7] . Hence, although lithium may appear to decrease neuroplasticity markers such as MARCKS and GAP-43, it may enhance synaptic strength by increasing NTF expression. In addition, lithium also elongates cilia in PC12 neuronal cells and human astrocytes via cAMP singling pathway [101] . Also, lithium has been observed to promote synapse formation in hippocampus, independent of PKC activity [102] . Hence, lithium may partly influence neuroplasticity through PKC-independent mechanisms. GAP-43 is also implicated in neurite outgrowth during neuronal differentiation and in synaptic plasticity [103, 104] , since loss of function of GAP-43 inhibits neurotransmitter release [105] . GAP-43 is regulated by PKC protein, but it acts as an adaptor that binds to membrane lipid-rafts [106] . GAP-43 is also expressed in astrocytes and is also regulated by PKC [107] . GAP-43 levels are found to be decreased in postmortem samples of hippocampi from patients with BD in comparison with matched controls indicating impaired neuroplasticity [108] . On the other hand, lithium administration decreases GAP-43 expression in both immortalized hippocampal cell culture and in the frontal cortex and hippocampus through myo-inositol depletion [109] . However, its role in BD pathophysiology remains unknown, since the decrease in GAP-43 could be a treatment effect of lithium or an independent marker of impaired synaptic plasticity in BD. Further research is needed to address these issues.
MARCKS is a membrane-bound actin crosslinking protein that regulates vesicular trafficking and mobility of structural phospholipids such as phosphatidylinositol-4,5-bisphosphate (PIP2) in the membrane plane [110, 111] . MARCKS undergoes dissociation from the membrane and translocates to cytoplasm after phosphorylation by PKC [112] . An increase in PKC-mediated phosphorylation of MARCKS (pMARCKS) in the PFC was observed in AMPH treatment and PSD models of mania [47] . In patients with BD, treatment with tricyclic antidepressants (TCA) can often induce mania [113] . The administration of imipramine, a TCA, in rats increases the pMARCKS in the PFC [47] . Myo-inositol is an important component of PIP2 and provides the building blocks for inositol phosphate-mediated second messenger signaling [114] . Lithium treatment decreases the levels of MARCKS [115] through myo-inositol depletion [109] . Lithium also reversed the increase in pMARCKS in the PFC of AMPH and imipramine-treated and sleep-deprived rodents [47] . Valproic acid actions, on the other hand, are independent of myo-inositol [116] but also decrease MARCKS expression [117] . These observations highlight that although lithium and valproic acid have different mechanisms of actions, they share PKC as a target and affect its downstream signaling.
SNAP-25 is a t-SNARE protein that regulates neurotransmitter release by exocytosis [118] and is a major PKC substrate [119, 120] . PKC activation with PMA has been shown to increase SNAP-25 phosphorylation and redistribute dopamine-and acetylcholine-containing vesicles to plasma membrane, along with increased depolarization-induced dopamine release [121] . Phosphorylation of SNAP-25 was increased in cerebral cortex, hippocampus, and amygdala of mice following cold-water restraint stress [120] . Interestingly, increased phosphorylation of SNAP-25 in both hippocampus and PFC was also seen in a PSD model of mania, suggesting increased neurotransmitter release [48] . In fact, in support of this proposition, euthymic BD patients have been observed to have enhanced dopamine release compared with healthy subjects [122] . The effect of mood stabilizers or TMX on SNAP-25 phosphorylation, however, remains to be studied.
Glutamatergic excitotoxicity is another putative mechanisms proposed in BD pathophysiology [123] . A metaanalysis revealed that glutamate levels were increased in several brain regions of patients with BD [124] . Regarding glutamatergic signaling, AMPH-treated, sleep-deprived, and imipramine-treated rats showed that the increase in the phosphorylation of N-methyl-D -aspartate (GluN1S896) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (GluA1T840) receptor in the PFC was PKC mediated, leading to an increase in trafficking of these receptors to neuronal membranes [47] . Moreover, the same study showed that these events were inhibited by chronic (3-week) lithium treatment, providing another explanation for antimanic properties of lithium [47] .
Oxidative stress secondary to mitochondrial dysfunction is also implicated in BD pathophysiology [125] . In a meta-analysis, oxidative stress markers were observed to be increased in BD [126] . Quercetin is a flavanol that contains a polyphenolic structure that scavenges free radicals and hence, acts as an antioxidant, and it also exhibits pleiotropic nonspecific PKC inhibition [127] . Kanazawa et al. [53] showed that the quercetin administration was able to reverse the increase in lipid peroxidation in PFC, hippocampus, and striatum in a mouse model of mania induced by PSD. Quercetin also blocked methylphenidate-induced hyperlocomotion and oxidative stress in PFC, hippocampus, and striatum of mice [51] . It appears that oxidative stress is downstream to PKC signaling as TMX, a selective PKC inhibitor, also prevented and reversed oxidative stress in AMPH-treated rats [50] .
GSK-3beta is a constitutively active kinase with high basal activity and inactivated by phosphorylation [128] . GSK was first characterized for its role in glycogen metabolism but later earned its major recognition in developmental and cancer biology [128] . GSK-3beta is inhibited by both lithium [129] and valproic acid [130] . Lithium directly inhibits GSK-3beta at supra-therapeutic levels [131] and indirectly, at therapeutically relevant concentration, through phosphorylation of its key inhibitory site, serine-9 via PI3-PKC pathway [132] . The effect of lithium on GSK-3beta expression, however, may be brain region dependent. For example, in a recent in vivo experiment, we observed that lithium treatment de-creased total GSK-3beta expression in PFC but increased it in the hippocampus [7] . Nevertheless, AMPH treatment significantly increased GSK-3beta expression and decreased phosphorylated GSK-3beta (pGSD-3beta -inactive form) in all mood-regulating frontolimbic structures [7] , suggesting a GSK-3beta hyperactivity. Lithium and TMX administration reversed the AMPH-induced overactivation of GSK-3beta, suggesting that the increase in the GSK-3beta activity may be partly mediated by PKC [7] . Inhibition of GSK has also been shown to be neuroprotective by inhibition of apoptotic signaling and neurodegeneration [133] , and is considered as one of the key future therapeutic avenues for BD [134] .
The cyclic AMP (c-AMP)/protein kinase A (PKA)/c-AMP response element binding protein (CREB) pathway plays an important role in synaptogenesis and synaptic plasticity [135] . Although the c-AMP /PKA/CREB pathway is not the focus of this review, it is important to note its cross-talk with phospholipase C (PLC)/PKC signaling pathway. The G protein-bound adenylate cyclase catalyzes the conversion of ATP into c-AMP, which activates PKA, which in turn regulates several intracellular processes including phosphorylation of CREB, a transcription factor [136] . Increased c-AMP signaling is also implicated in BD [137] [138] [139] . In vivo microdialysis revealed that direct activation of PKC by PMA in the frontal cortex and hippocampus increases c-AMP in the dialysate [39] . Moreover, AMPH-treated rats show a decreased PKA and CREB phosphorylation in the frontolimbic circuit (PFC, hippocampus, amygdala, and striatum), and this decrease was prevented and reversed by lithium and TMX treatment [7] .
Genetics
BD has high familial inheritability, and recent advances in genomic studies may provide insights into the genetic basis of BD [140] . Genetic studies have also implicated PKC in BD [141] [142] [143] . In the following section, we will briefly discuss putative gene candidates involving activator protein 1 (AP-1), GSK-3beta, DAG kinase eta (DGKeta), and PKC interacting protein/histidine triad nucleotide binding protein 1 (PKCI/HINT1), that highlight putative genetic mechanisms underlying BD.
AP-1 is a transcription factor, comprising Fos and Jun subunits [144] , that regulates gene expression and neuroplasticity and is implicated in several chronic cardiovascular [145] and psychiatric illnesses [144] . AP-1 has been shown to increase its DNA binding in response to exposure to lithium and valproic acid [146] [147] [148] and increase the translation of AP-1-regulated genes in vitro and in vivo [39, 116] . Moreover, PKC signaling influences this key epigenetic effect by regulating phosphorylation Jun proteins [149] .
DGKeta gained attention after several genome-wide association studies found DGKeta as one of the replicated risk genes in BD [150] . DGKeta is coded by DGKH gene, and polymorphisms in the DGKH gene have been observed to confer susceptibility to BD [151] . DGK risk haplotypes in humans are also associated with enlarged amygdala in BD patients [152] . Moreover, DGK is involved in biosynthesis of glycerophospholipids (GPLs) [153] . Alterations in membrane GPL composition has been implicated in several neuropsychiatric disorders, including BD [154] . DGKeta was observed to negatively regulate the PLC/PKC pathway by converting inactivating DAG, a cofactor of PKC, to phosphatidic acid [155] [156] [157] , hence preventing overactivation of PKC cascade. Recently, DGKeta and PKC have been shown to reciprocally inhibit each other [158] . Specifically, in HEK 293 cells, DGKeta overexpression increased and PKC activation decreased G-protein-coupled receptor (GPCR) signaling [158] . DGKeta overexpression prevented PKC activation-induced desensitization of GPCR signaling [158] . Pharmacological activation of PKC, in turn, prevented DGKeta overexpression-induced enhanced GPCR (muscarinic and purinergic) signaling [158] ( Fig. 2 ) . In the light of significant evidence in support of PKC hyperactivity in BD, hypoactive DGKeta function can be hypothesized in BD [159] . In fact, DGKeta knockout mice 119 display manic features that were ameliorated by lithium [160] . In contrast, patients with BD show increased DGKeta expression [161] . Given a reciprocal regulation between DGK and PKC [162] , a compensatory increase in DGK expression can be hypothesized. However, future investigations are needed to further clarify the role of DGKeta in the pathophysiology of BD [163] .
PKCI/HINT1 is another gene candidate implicated in BD. PKCI/HINT1 is a haploinsufficient tumor suppressor gene [164] . In a meta-analysis, PKCI/HINT1 expression in dorsolateral PFC was found to be decreased in BD [165] . PKCI/HINT1 knockout mice do not show baseline hyperlocomotion but display enhanced locomotor response to AMPH treatment [166] , increased risk-taking and antidepressant-like behavior [167] , emotional arousal, and PKC expression [168] . As increased PKCI/HINT1 expression shows antineoplastic properties in colon and hepatic cells, a hypoactive PKCI/HINT1 may indicate activated neoplastic signaling that underlies BD [164] .
Suicidality is a common occurrence in patients with BD, and PKC is also implicated in suicidal behavior in patients with BD [169, 170] . In a meta-analysis of 8,700 patients, both unipolar depression and BD were found to be associated with suicidality and gene locus for PKCε [170] . Moreover, using the convergent functional genomics approach, MARCKS, a PKC substrate [171] , was found to be one of the 6 peripheral biomarkers that predict past and future hospitalization in relation to suicidality in patients with BD [172] . This observation further implicates hyperactive PKC signaling in the etiopathogenesis of BD.
Conclusion
An understanding of the pathogenesis of BD is needed to develop more effective therapies. Research in the past decade has identified several mechanisms such as apoptotic, neoplastic, inflammatory, energy homeostasis, synaptic neurotransmission, and oxidative balance to be involved in the pathophysiology of BD. However, PKC appears to play a central role in all these processes [173] . This attribution is supported by the effectiveness of PKC inhibitors, such as TMX and endoxifen, in treating manic symptoms in humans. Nevertheless, future research is warranted to develop safe and specific therapies for this devastating disorder.
